Evidence map›Paper›PMID 38478269›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Recombinant Expression and Overproduction of Transmembrane β-Barrel Proteins.

Ina Meuskens, Jack C Leo, Dirk Linke

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Ina MeuskensDepartment of Biosciences, Section for Genetics and Evolutionary Biology, University of Oslo, Oslo, Norway.
Jack C LeoAntimicrobial Resistance, Omics and Microbiota Group, Department of Biosciences, Nottingham Trent University, Nottingham, UK.
Dirk LinkeDepartment of Biosciences, Section for Genetics and Evolutionary Biology, University of Oslo, Oslo, Norway. dirk.linke@ibv.uio.no.
ETH Zurich · CHNottingham Trent University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmembrane β-barrel proteins reside in the outer membrane of Gram-negative bacteria and are thus in direct contact with the environment. Because of that, they are involved in many key processes stretching from cellular survival to virulence. Hence, they are an attractive target for the development of novel antimicrobials, in addition to being of fundamental biological interest. To study this class of proteins, they are often required to be expressed in Escherichia coli. Recombinant expression of β-barrel proteins can be achieved using two fundamentally different strategies. The first alternative uses a complete coding sequence that includes a signal peptide for targeting the protein to its native cellular location, the bacterial outer membrane. The second alternative omits the signal peptide in the gene, leading to mislocalization and aggregation of the protein in the bacterial cytoplasm. These aggregates, called inclusion bodies, can be solubilized and the protein can be folded into its native form in vitro. In this chapter, we present example protocols for both strategies and discuss their advantages and disadvantages.

Indexed as

Escherichia coli ProteinsProtein FoldingBacterial Outer Membrane ProteinsEscherichia coliProtein Sorting SignalsBacterial Outer Membrane ProteinsEscherichia coli ProteinsProtein Sorting SignalsDetergentsInclusion bodiesMembrane insertionMembrane protein foldingOuter membrane proteinProtein expression

Identifiers

PMID38478269
OpenAlexW4392776208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.